Arcline sells Resolution Medical to Resonetics, boosts capability

Arcline has struck a definitive agreement to divest its portfolio company Resolution Medical to precision manufacturer Resonetics, a deal that combines high‑complexity device engineering with larger-scale contract manufacturing. The transaction, announced Thursday, is expected to conclude in the first quarter of 2026, subject to regulatory clearance and customary closing conditions.

Resolution Medical, headquartered in Fridley, Minnesota, employs roughly 240 people, including more than 100 engineers, and provides end‑to‑end design, prototyping, bio‑simulation and finished device production for Class II and III devices. Its footprint covers fast‑growing clinical areas such as structural heart, cardiology and vascular, electrophysiology and neuromodulation—segments that are attracting strong R&D and commercial investment from device makers.

For strategic acquirers, the value is clear: adding complex design and early‑stage engineering capability shortens development cycles and reduces time to first‑in‑human and regulatory submissions. Kevin Kelly, CEO of Resonetics, framed the move as a capability play, saying the purchase will expand Resonetics’ integrated offerings for customers pursuing neuromodulation and structural heart solutions. Peter Herman, CEO of Resolution Medical, stressed continuity of mission and customer support as the two teams join.

The sale fits a wider trend of consolidation in the medical device contract manufacturing market, where strategic buyers are buying engineering‑heavy partners to capture more of the product lifecycle. Outsourced manufacturing and engineering for complex implants and interventional devices have seen rising demand; industry observers note double‑digit growth in subsegments like neuromodulation and structural heart as patient populations age and minimally invasive therapies proliferate.

Financial and legal advisers to the transaction are on record: Piper Sandler & Co. acted as financial adviser to Resolution Medical, while Bass, Berry & Sims PLC and Fredrikson & Byron P.A. served as legal counsel. The buyer, Resonetics, is a strategic acquirer rather than a private equity investor; the seller is the growth‑oriented buyout firm Arcline, which manages roughly $20 billion in assets and has pursued a strategy of building durable industrial platforms across specialist sectors.

The deal strengthens Resonetics’ ability to provide vertically integrated services from concept through commercial production, an attractive value proposition for device companies aiming to outsource more of their development pipeline. For Arcline, the exit is consistent with harvesting value from a platform that scaled technical capability and engineering talent. Regulators’ review and the integration process will determine near‑term operating continuity, but the combination positions the enlarged Resonetics to capture a larger share of the high‑value medtech outsourcing market.